GB2596884B - A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine - Google Patents

A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine Download PDF

Info

Publication number
GB2596884B
GB2596884B GB2019241.5A GB202019241A GB2596884B GB 2596884 B GB2596884 B GB 2596884B GB 202019241 A GB202019241 A GB 202019241A GB 2596884 B GB2596884 B GB 2596884B
Authority
GB
United Kingdom
Prior art keywords
dimethyltryptamine
methoxy
pharmaceutical composition
benzoate salt
benzoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2019241.5A
Other versions
GB202019241D0 (en
GB2596884B8 (en
GB2596884A (en
GB2596884A8 (en
Inventor
Feilding-Mellen Cosmo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beckley Psytech Ltd
Original Assignee
Beckley Psytech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beckley Psytech Ltd filed Critical Beckley Psytech Ltd
Publication of GB202019241D0 publication Critical patent/GB202019241D0/en
Priority to KR1020237001336A priority Critical patent/KR20230024378A/en
Priority to BR112022025306A priority patent/BR112022025306A2/en
Priority to EP21735380.4A priority patent/EP3941904A1/en
Priority to EP21735379.6A priority patent/EP3941583B9/en
Priority to PCT/GB2021/051476 priority patent/WO2021250435A1/en
Priority to EP23157604.2A priority patent/EP4279070A3/en
Priority to CN202180055398.7A priority patent/CN116056762A/en
Priority to IL298871A priority patent/IL298871A/en
Priority to CA3187020A priority patent/CA3187020A1/en
Priority to PCT/GB2021/051475 priority patent/WO2021250434A1/en
Priority to JP2022576811A priority patent/JP2023530292A/en
Priority to AU2021289147A priority patent/AU2021289147A1/en
Publication of GB2596884A publication Critical patent/GB2596884A/en
Priority to US17/660,981 priority patent/US11518743B2/en
Priority to US17/660,873 priority patent/US11518742B2/en
Priority to US17/817,548 priority patent/US11603353B2/en
Publication of GB2596884B publication Critical patent/GB2596884B/en
Priority to US17/935,256 priority patent/US11680044B2/en
Priority to US18/162,976 priority patent/US20230348381A1/en
Priority to US18/310,822 priority patent/US20230382858A1/en
Application granted granted Critical
Publication of GB2596884B8 publication Critical patent/GB2596884B8/en
Publication of GB2596884A8 publication Critical patent/GB2596884A8/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
GB2019241.5A 2020-06-12 2020-12-07 A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine Active GB2596884B8 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
JP2022576811A JP2023530292A (en) 2020-06-12 2021-06-14 Compositions containing the benzoate salt of 5-methoxy-N,N-dimethyltryptamine
EP21735380.4A EP3941904A1 (en) 2020-06-12 2021-06-14 Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
BR112022025306A BR112022025306A2 (en) 2020-06-12 2021-06-14 COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXIN, N-DIMETHYLTRIPTAMINE
EP21735379.6A EP3941583B9 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
IL298871A IL298871A (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
EP23157604.2A EP4279070A3 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
CN202180055398.7A CN116056762A (en) 2020-06-12 2021-06-14 Compositions comprising benzoates of 5-methoxy-N, N-dimethyltryptamine
PCT/GB2021/051476 WO2021250435A1 (en) 2020-06-12 2021-06-14 Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
CA3187020A CA3187020A1 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
PCT/GB2021/051475 WO2021250434A1 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
KR1020237001336A KR20230024378A (en) 2020-06-12 2021-06-14 A composition comprising the benzoate salt of 5-methoxy-N,N-dimethyltryptamine
AU2021289147A AU2021289147A1 (en) 2020-06-12 2021-06-14 Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
US17/660,873 US11518742B2 (en) 2020-06-12 2022-04-27 Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
US17/660,981 US11518743B2 (en) 2020-06-12 2022-04-27 Pharmaceutical composition comprising 5-methoxy-N,N-dimethyltryptamine
US17/817,548 US11603353B2 (en) 2020-06-12 2022-08-04 Composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
US17/935,256 US11680044B2 (en) 2020-06-12 2022-09-26 Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
US18/162,976 US20230348381A1 (en) 2020-06-12 2023-02-01 Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
US18/310,822 US20230382858A1 (en) 2020-06-12 2023-05-02 Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2008961.1A GB202008961D0 (en) 2020-06-12 2020-06-12 Pharmaceutical composition

Publications (5)

Publication Number Publication Date
GB202019241D0 GB202019241D0 (en) 2021-01-20
GB2596884A GB2596884A (en) 2022-01-12
GB2596884B true GB2596884B (en) 2022-09-21
GB2596884B8 GB2596884B8 (en) 2023-08-09
GB2596884A8 GB2596884A8 (en) 2023-08-09

Family

ID=71835429

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB2008961.1A Ceased GB202008961D0 (en) 2020-06-12 2020-06-12 Pharmaceutical composition
GB2019241.5A Active GB2596884B8 (en) 2020-06-12 2020-12-07 A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GBGB2008961.1A Ceased GB202008961D0 (en) 2020-06-12 2020-06-12 Pharmaceutical composition

Country Status (1)

Country Link
GB (2) GB202008961D0 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
CA3160337C (en) 2019-11-07 2023-08-29 Small Pharma Ltd Method of synthesis
US20210378969A1 (en) 2020-06-02 2021-12-09 Small Pharma Ltd. Therapeutic solid dosage forms
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
CA3187020A1 (en) 2020-06-12 2021-12-16 Beckley Psytech Limited Composition comprising a benzoate salt of 5-methoxy-n,n-dimethyltryptamine
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008003028A2 (en) * 2006-06-28 2008-01-03 Chelsea Therapeutics, Inc. Pharmaceutical compositions comprising droxidopa
WO2012173701A1 (en) * 2011-06-16 2012-12-20 President And Fellows Of Harvard College Novel rodent control agents and uses thereof
WO2013063492A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008003028A2 (en) * 2006-06-28 2008-01-03 Chelsea Therapeutics, Inc. Pharmaceutical compositions comprising droxidopa
WO2012173701A1 (en) * 2011-06-16 2012-12-20 President And Fellows Of Harvard College Novel rodent control agents and uses thereof
WO2013063492A1 (en) * 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer

Also Published As

Publication number Publication date
GB202019241D0 (en) 2021-01-20
GB2596884B8 (en) 2023-08-09
GB202008961D0 (en) 2020-07-29
GB2596884A (en) 2022-01-12
GB2596884A8 (en) 2023-08-09

Similar Documents

Publication Publication Date Title
GB2596884B8 (en) A pharmaceutical composition comprising a benzoate salt of 5-methoxy-N,N-dimethyltryptamine
BR112022025306A2 (en) COMPOSITION COMPRISING A BENZOATE SALT OF 5-METHOXIN, N-DIMETHYLTRIPTAMINE
IL288617A (en) Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
EP3615011A4 (en) Pharmaceutical composition for in vivo delivery, method of preparation of a substantially waterinsoluble pharmacologically active agent
EP4132511A4 (en) Pharmaceutical compositions comprising meloxicam
EP2871187A4 (en) Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient
EP4079298A4 (en) Kit for preparing nanoparticle composition for drug delivery, comprising polylactic acid salt
GB202010409D0 (en) Pharmaceutical compounds
GB2593902B (en) Salt of a pharmaceutical compound
JO3435B1 (en) Solid pharmaceutical composition comprising amlodipine and losartan
EP4190310A4 (en) Stable pharmaceutical preparation
WO2015131814A3 (en) Use of [(aryloxy)(heteroaryl)]methylpiperidine derivatives in manufacture of medicaments for treatment of depression
EP3965771A4 (en) Finished pharmaceutical dosage form of a methenamine salt such as methenamine mandelate
EP4079305A4 (en) Application of compound in drug preparation
WO2012153347A3 (en) Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate
GB202107924D0 (en) A pharmaceutical salt
GB202015187D0 (en) A pharmaceutical salt
GB202306256D0 (en) 5-Methoxy-N,N-Dimethyltryptamine Formulations
EP4205765A4 (en) Stable pharmaceutical preparation
GB202304224D0 (en) Osmotic drug delivery implants
PL3902541T3 (en) Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
ZA201803722B (en) Pharmaceutical composition containing, as active ingredient, 7-azaindolin-2-one derivative or pharmaceutically acceptable salt thereof
GB202301180D0 (en) Salt of a pharmaceutical compound
EP3949959A4 (en) Pharmaceutical composition comprising trimebutine or pharmaceutically acceptable salt thereof as active ingredient for prevention or treatment of cancer
HK1184050A1 (en) Pharmaceutical form for combating chemical submission of a medicament

Legal Events

Date Code Title Description
S13A Application for inventor to be mentioned (section 13(1)/patents act 1977)

Free format text: APPLICATION FILED; APPLICATION UNDER RULE 10(2) FOR INVENTOR TO BE MENTIONED FILED ON 13 OCTOBER 2022 BY BECKLEY PSYTECH LIMITED

S13A Application for inventor to be mentioned (section 13(1)/patents act 1977)

Free format text: APPLICATION ALLOWED; IN A DECISION OF THE COMPTROLLER DATED 03 AUGUST 2023, THE COMPTROLLER FOUND THAT TIMOTHY MASON SHOULD BE MENTIONED AS A JOINT INVENTOR IN RESPECT OF PUBLISHED PATENT APPLICATION AND GRANTED PATENT GB2596884. THE COMPTROLLER ORDERED THAT AN ADDENDUM SLIP BE PREPARED FOR THE PUBLISHED PATENT APPLICATION AND GRANTED PATENT ACCORDINGLY.